Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain ...

Kite, a Gilead Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory no ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or ...

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

The SMC’s backing for Yescarta is “further good news for people affected by lymphoma as it means there is wider access to CAR-T cell therapy in Scotland,” commented Stephen Scowcroft ...

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis ...

Speaking about the news, she said ... relapse and the harsh side effects of existing treatments. The approval of Yescarta means more patients in Scotland can be treated with CAR-T therapy ...

The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult ... including both those eligible and ineligible for stem cell transplant. This ...